Congress Materials – European Congress of Rheumatology (EULAR 2026)
2026 European Congress of Rheumatology | Jun 3-6 | London, UK
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
12-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Active Psoriatic Arthritis: Real-World Data from the PPD CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease, Alexis Ogdie, John Tesser, Timothy P. Fitzgerald, Elizabeth Adamson, Soumya D. Chakravarty, Robert R. McLean, Taylor S. Blachley, Melissa Eliot, Skyler S. Peterson, Aaron Broadwell, Kurt Oelke, Arthur Kavanaugh, Joseph F. Merola
This document will be available after June 3rd 2026
Achievement of cDAPSA Low Disease Activity/Remission and Association With Structural Damage Progression in Guselkumab-Treated Participants With Active and Erosive Psoriatic Arthritis: Post hoc Analysis Through Week 48 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Christopher T Ritchlin, Laura C Coates, Philip J Mease, Alexa P Kollmeier, Weihong Hu, Soumya D Chakravarty, Stacey Fitch, Karissa Lozenski, Alexis Ogdie, Proton Rahman
This document will be available after June 3rd 2026
Age at Onset and Its Association With Damage Accrual in Systemic Lupus Erythematosus (SLE): Insights From 5 Registries in the Lupus Federated Data Network (LupusNet)
Kaleb Michaud, Sarah Gasman, Federico Zazzetti, Ashley Orillion, Anna Sheahan, Clair Blacketer, Michel van Speybroeck, Reyhan Sonmez, Erika Noss, Manuel F Ugarte-Gil, Rocio V Gamboa-Cardenas, Victor Pimentel-Quiroz, Guillermo A Pons-Estel, Diana C Fernández-Ávila, Carmen Funes Soaje, Henrique Ataide Mariz, Edgard Torres dos Reis-Neto, Carlos Alberto Cañas, Gerardo Quintana-Lopez, Miguel Ángel Saavedra, Margarita Portela Hernández, Claudia Mora-Trujillo, Patricia Katz, Rangi Kandane-Rathnayake, Eric Morand, Worawit Louthrenoo, Alberta Hoi, Mandana Nikpour, Sandra Navarra, Chak Sing Lau, Laniyati Hamijoyo, Yeong-Jian Jan Wu, Yasuhiro Katsumata, Iñigo Rúa-Figueroa, José María Pego-Reigosa, Raúl Menor Almagro, Jaime Calvo Alén, María Galindo-Izquierdo, Fernando Alonso
This document will be available after June 2nd 2026
Biomarker-Driven Insights From the Phase 2a AFFINITY Study Evaluating Guselkumab + Golimumab Combination Therapy Versus Guselkumab Monotherapy in Psoriatic Arthritis
Iain B. McInnes, Loqmane Seridi, Christopher T. Ritchlin, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Karissa Lozenski, Soumya D. Chakravarty, Eric Wadman, Carolyn Cuff, Matthew J. Loza, Warner Chen, Sheng Gao, Lianne S. Gensler, Philip J. Mease, Danielle Murphy, Jose U. Scher
This document will be available after June 2nd 2026
Biomarker-Driven Insights to Clinical Response in DAHLIAS: a Nipocalimab Trial for Sjögren’s Disease
Hal Scofield, He Li, Jacques-Eric Gottenberg, David Galbraith, Keying Ma, Lynn Tomsho, Chris Sisk, Matthew J. Loza, Jonathan J. Hubbard, Kim Campbell, Dawn Waterworth, Sheng Gao, Carolyn Cuff, Steven Leonardo, Kathy Sivils
This document will be available after June 3rd 2026
Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjögren’s Disease Treated With Nipocalimab: Post-hoc Analysis of the DAHLIAS Study
Faye Yu, Eugene Myshkin, Jonathan J. Hubbard, Kim Campbell, Jacques-Eric Gottenberg, Matthew J. Loza, Dessislava Dimitrova, Carolyn Cuff, Sheng Gao
This document will be available after June 2nd 2026
Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
Marco Ulises Martínez Martínez, Karen Roberts, Rosana Quintana, Marina Scolnik, Carmen Funes Soaje, Paula Alba, Verónica Saurit, Mercedes Argentina García, Guillermo A. Berbotto, Verónica Bellomio, Eduardo Mario Kerzberg, Graciela Noemí Gómez, Cecilia Nora Pisoni, Vicente Juárez, Ana Malvar, Nilzio Antonio da Silva, Odirlei Andre Monticielo, Henrique Ataide Mariz, Francinne Machado Ribeiro, Eduardo F. Borba, Eloisa Bonfa, Edgard Torres dos Reis-Neto, Iris Guerra Herrera, Loreto Massardo, Gustavo Aroca Martínez, Lorena Gómez Escorcia, Carlos A. Cañas, Gerardo Quintana-Lopez, Carlos Enrique Toro Gutiérrez, Mario Javier Moreno Alvarez, Miguel Ángel Saavedra, Margarita Portela Hernández, Hilda Fragoso-Loyo, Luis H. Silveira, Ignacio García de la Torre, Carlos Abud-Mendoza, Jorge A. Esquivel Valerio, Isabel Acosta Colman, Astrid Paats, Claudia Mora Trujillo, Manuel F. Ugarte-Gil, Armando Calvo Quiroz, Roberto Muñoz Louis, Martín Rebella, Álvaro Danza, José A. Gómez-Puerta, Federico Zazzetti, Ashley Orillion, Guillermo Pons-Estel, Ingris Peláez-Ballestas
This document will be available after June 3rd 2026
Effect of Guselkumab and Golimumab Combination Therapy on Magnetic Resonance Imaging-Detected Inflammation and Damage in Phalangeal Joints of the Hands and Feet and Entheses of the Heels Among Participants With Active Psoriatic Arthritis: Findings From the Phase 2a AFFINITY Study
Jeremy Wellen, Maoji Li, Tong Wang, Edaire Cheng, Bei Zhou, Elena Reynoso, Loqmane Seridi, Jose U. Scher, Christopher T. Ritchlin, Paul Bird, Mikkel Østergaard
This document will be available after June 4th 2026
Effects of Guselkumab on Patient-Reported Outcomes in Biologic-Naïve Participants With Active and Erosive Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Proton Rahman, Phillip J. Mease, Christopher T. Ritchlin, Alexa P. Kollmeier, Yusang Jiang, Soumya D. Chakravarty, Evan Leibowitz, Karissa Lozenski, Arthur Kavanaugh, Laura C. Coates
This document will be available after June 3rd 2026
Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis and Inadequate Response/Intolerance to One Prior Tumor Necrosis Factor Inhibitor Through 1 Year of the SOLSTICE Study
Alice B. Gottlieb, Joseph F. Merola, Phillip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Soumya D. Chakravarty, Yanli Wang, Yevgeniy Krol, Stacey Fitch, Alexis Ogdie
This document will be available after June 3rd 2026
Efficacy and Safety of Subcutaneous Ustekinumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis: Results of the Open-label, Phase 3 PSUMMIT-Jr Study Through Week 52
Nicolino Ruperto, Daniel P. Hawley, Ozgur Kasapcopur, Sandrine Compeyrot-Lacassagne, Hafize Emine Sönmez, Berta Paula Magallares López, Ozge Basaran, Alejandro Brigante, Samundeeswari Deepak, Giovanni Filocamo, Kerstin Nott, Sarah Ringold, Samantha Howard, Valerie Smith, Katherine Berezny, Jocelyn H. Leu, Daniel J. Lovell, Alberto Martini, and Hermine Brunner, on behalf of the Pediatric Rheumatology Collaborative Study Group, PRCSG, and Paediatric Rheumatology International Trials Organisation, PRINTO
This document will be available after June 3rd 2026
Efficacy of Guselkumab Assessed by Composite Indices in Participants With Active and Erosive Psoriatic Arthritis: Analyses Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Laura C Coates, Phillip J Mease, Christopher T Ritchlin, Alexa P Kollmeier, Yusang Jiang, Soumya D Chakravarty, Elizabeth Adamson, Karissa Lozenski, Arthur Kavanaugh, Proton Rahman
This document will be available after June 3rd 2026
Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
This document will be available after June 2nd 2026
Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials
Iain B. McInnes, Linda Stein Gold, Robert Bissonnette, Mark G. Lebwohl, Ofelia Reyes-Servin, Joseph Cafone, Ya-Wen Yang, Soumya D. Chakravarty, Charles Iaconangelo, Shu Li, Tasneam Shagroni, Karissa Lozenski, April W. Armstrong, Joseph F. Merola
This document will be available after June 2nd 2026
Intravenous Cyclophosphamide Versus Mycophenolate Mofetil for Induction Therapy in Incident Lupus Nephritis: Data From a Multi-Ethnic, Multinational Latin American Cohort (GLADEL 2.0)
Victor Pimentel-Quiroz, Guillermina B. Harvey, Marina Scolnik, Carmen Funes Soaje, Carla Andrea Gobbi, Verónica Saurit, Valeria Arturi, Leonel Berbotto, Rosana Quintana, Luciana Gonzalez Lucero, Eduardo Mario Kerzberg, Nicolás Perez, Cecilia Nora Pisoni, Vicente Juárez, Joaquín Martinez Serventi, Ana Carolina O. S. Montandon, Andrese Aline Gasparin, Henrique Ataide Mariz, Evandro Mendes Klumb, Eduardo F. Borba, Eloisa Bonfa, Edgard Torres dos Reis-Neto, Iris Guerra Herrera, Milena Mimica, Gustavo Aroca Martínez, Antonio iglesias Gamarra, Carlos Alberto Cañas, Gerardo Quintana-Lopez, Carlos Enrique Toro Gutiérrez, Mario Javier Moreno Alvarez, Reyna Elizabeth Sánchez-Briones, Margarita Portela Hernández, Fragoso-Loyo Hilda, Luis M. Amezcua-Guerra, YelitzaC.González-Bello, Jorge A. Esquivel Valerio, Isabel Acosta Colman, Jhonatan Losanto, Claudia Mora-Trujillo, Manuel F. Ugarte-Gil, Armando Calvo Quiroz, Roberto Muñoz Louis, Martín Rebella, Álvaro Danza, Federico Zazzetti, Ashley Orillion, Bernardo A. Pons-Estel, Luis Catoggio.
This document will be available after June 2nd 2026
Joint Disease Activity Trajectories in Participants with Active Psoriatic Arthritis Treated with Guselkumab: A Bayesian Analysis of Three Phase 3, Randomized, Controlled Studies
Iain B. McInnes, Mohamed Sharaf, Xenofon Baraliakos, Julio Ramírez, Emmanouil Rampakakis, Karissa Lozenski, Carlo Selmi, Laura C. Coates
This document will be available after June 2nd 2026
Nipocalimab in SLE: First-in-Class Efficacy and Safety Results Demonstrating Proof of Concept for FcRn Blockade From the Phase 2 JASMINE-SLE Study
Nipocalimab in SLE: First-in-Class Efficacy and Safety Results Demonstrating Proof of Concept for FcRn Blockade From the Phase 2 JASMINE-SLE Study
This document will be available after June 6th 2026
Persistence, Effectiveness, Safety, and Patient Reported Impact of Guselkumab and IL-17 Inhibitors in Psoriatic Arthritis: Full Population Results of the PsABIOnd Global Observational Study Over 12 Months
Laure Gossec, Mohamed Sharaf, Frank Behrens, Ennio Lubrano, Mitsumasa Kishimoto, Xenofon Baraliakos, Ruben Queiro Silva, Emmanouil Rampakakis, László Köleséri, Karissa Lozenski, Enrique R. Soriano, Proton Rahman, Stefan Siebert
This document will be available after June 2nd 2026
Pregnancy Outcomes in Maternal Exposure to Guselkumab: Review of Cases Reported to the Company Global Safety Database
Uma Mahadevan, Millie Long, Mette Julsgaard, Connie Lin, Anja Geldhof, Laura C. Coates, Mauricio Rosas Ballina, Hewei Li, Javier P. Gisbert, María Chaparro
This document will be available after June 4th 2026
Psoriatic Skin and Nail Outcomes With Guselkumab Treatment in Participants With Active and Erosive Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Joseph F. Merola, Christopher T. Ritchlin, Philip J. Mease, Proton Rahman, Alexa Kollmeier, Yusang Jiang, Soumya D. Chakravarty, Karissa Lozenski, April W. Armstrong, Tina Bhutani, Alexis Ogdie, Laura C. Coates
This document will be available after June 3rd 2026
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Philip J Mease, Jessica Walsh, Timothy P Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Pavithra Srinivas, Bruno Emond, Arthur Voegel, Yuxi Wang, Sinia Sareen, Helena Huang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F Merola
This document will be available after June 3rd 2026
Sharp.AI: Longitudinal AI-Based Evaluation of Radiographic Progression in Psoriatic Arthritis
Zijun Gao, Darshana Govind, Dimitri Kessler, Chaitanya Parmar, Kenneth Broos, Nicholas Fountoulakis, Xiaoqin Tang, Luiza Gabriel, Elizabeth Hsia, Gabriela Oana Cula, Lenore Noonan, Philip Murphy, Anna Beutler, Terence Rooney, Michael Deman, Peter Ory, Kristopher Standish, Robert Janiczek
This document will be available after June 2nd 2026
Structural Damage Progression and Clinical Response to Guselkumab in Participants With Active and Erosive Psoriatic Arthritis: Post hoc Analysis at Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Christopher T. Ritchlin, Proton Rahman, Laura C. Coates, Alexa P. Kollmeier, Yusang Jiang, Soumya D. Chakravarty, Elizabeth Adamson, Karissa Lozenski, Arthur Kavanaugh, Philip J. Mease
This document will be available after June 3rd 2026
Systemic Treatment Patterns in SLE: Associations With Disease Severity and Organ-Specific Activity Across 5 Registries in the Lupus Federated Data Network (LupusNet)
Guillermo A Pons-Estel, Sarah Gasman, Federico Zazzetti, Ashley Orillion, Anna Sheahan, Clair Blacketer, Michel van Speybroeck, Reyhan Sonmez, Erika Noss, Manuel F Ugarte-Gil, Rocio V Gamboa-Cardenas, Victor Pimentel-Quiroz, Romina E Nieto, Marina Scolnik, Eduardo F Borba, Loreto Massardo, Gustavo Aroca Martínez, Mario Javier Moreno Alvarez, Isabel Acosta Colman, Roberto Muñoz Louis, Álvaro Danza, Kaleb Michaud, Patricia Katz, Rangi Kandane-Rathnayake, Eric Morand, Worawit Louthrenoo, Alberta Hoi, Mandana Nikpour, Sandra Navarra, Chak Sing Lau, Laniyati Hamijoyo, Yeong-Jian Jan Wu, Yasuhiro Katsumata, Iñigo Rúa-Figueroa, José María Pego-Reigosa, Raúl Menor Almagro, Jaime Calvo Alén, María Galindo-Izquierdo, Fernando Alonso
This document will be available after June 2nd 2026
Treatment Patterns Before and During Pregnancy in Women With Sjögren’s Disease, Systemic Lupus Erythematosus, or Rheumatoid Arthritis: A Nationwide Population-Based Register Study in Sweden
Kelvin H.M. Kwok, Yangjun Liu, Selena Huang, Melanie H. Jacobson, Alexis Krumme, Rebecca Zaha
This document will be available after June 2nd 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.